Syntex (u.s.a.) Inc.

Syntex LLC

Hoffmann-la Roche Inc.

Pfizer Corporation

Roche Palo Alto LLC

Pharmacia Corporation

Brian H Vickery

John J Nestor

John J Nestor, Jr

John L Krstenansky

Teresa H Ho

Chinh T Bach

Gordon H Jones

Richard E Jones

Milan R Uskokovic

Keith Adrian Walker

Eric J Benjamin

Lynda M Sanders

Cherng-chyi Fu

Duane W Hallesy

Robin D Clark

Percy Sarwood Manchand

Shabbir T Anik

Mike Spedding

Pharmaceutical compositions of biologically active polypeptides in powder form suitable for nasal administration, comprising a therapeutically effective amount of a biologically active polypeptide and a water-soluble polysaccharide.

Intranasal administration of polypeptides in powdered form

This invention provides methods of bone healing and fracture repair comprising administering to a patient in need thereof an effective amount of a polypeptide analog of parathyroid hormone related peptide (PTHrP) and salts thereof, wherein amino acid residues 22-31 form an amphipathic &agr;-helix. Systemic administration is a preferred mode of delivery.

Fracture healing using pthrp analogs

Intranasal administration of LHRH polypeptides in powdered form

Synthetic polypeptide analogs of parathyroid hormone PTH, parathyroid hormone related peptide PTHrp, and of the physiologically active truncated homologs and analogs of PTH and PTHrp, in which amino acid residues (22-31) form an amphipathic .alpha.-helix, said residues (22-31) selected from hydrophilic amino acids (Haa) and lipophilic amino acids (Laa) ordered in the sequence:

Analogs of parathyroid hormone and parathyroid hormone related peptide:

Synthesis and use for the treatment of osteoporosis

Fluorinated Vitamin D.sub.3 analogs, intermediates for their preparation, compositions comprising the analogs and methods of treatment of osteoporosis and related conditions with these and related analogs are provided.

Fluorinated vitamin D3 analogs

Method for the treatment of corticosteroid induced osteopenia comprising

Process for recombinant production of PTH and PTHrp analogs

Synthetic nona- and decapeptide LHRH antagonist analogs are disclosed, having a sterically hindered guanidino-substituted arginyl or homoarginyl residue at position 8, with no arginyl substituent at position 6.

Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists

Synthetic polypeptide analogs of parathyroid hormone PTH, parathyroid hormone related peptide PTHrp, and of the physiologically active truncated homologs and analogs of PTH and PTHrp, in which amino acid residues (22-31) form an amphipathic .alpha.-helix, these residues (22-31) selected from hydrophilic amino acids (Haa) and lipophilic amino acids (Laa) ordered in the sequence:

A method for treating osteoporosis via administration of a compound of the formula, 1.alpha.-fluoro-25-hydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol, in an amount therapeutically effective to restore bone density to an asymptomatic level, without inducing hypercalciuria, hypercalcemia, or nephrotoxicity is provided.

Method for treating osteoporosis

Compounds of the formula ##STR1## wherein: m is an integer of 1-6;

Decahydro-8H-isoquino[2,1-g][1,6]naphthyridine and

Growing community of inventors

Cupertino, CA, United States of America

Brian H Vickery